Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing mice

Chanda, Nripen; Kan, Para; Watkinson, Lisa D.; Shukla, Ravi; Zambre, Ajit; Carmack, Terry; Engelbrecht, Hendrik; Lever, John R.; Katti, Kavita; Fent, Genevieve M.; Casteel, Stan W.; Smith, Charles J.; Miller, William H.; Jurisson, Silvia S.; Boote, Evan J.; Robertson, John; Cutler, Cathy S.; Dobrovolskaia, Marina A.; Kannan, Raghuraman

doi:10.1016/j.nano.2009.11.001

Cited by 203 publications

(155 citation statements)

References 38 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…On the molecular imaging front, gold with a K-edge at 80.7 keV has higher absorption than iodine (K-edge at 33 keV), thus minimizing bone and tissue interference, which results in better contrast with a lower x-ray dose (13). Our extensive in vivo studies (in mice, pigs, and dogs) have confirmed that gold nanoparticles (AuNPs) show significantly higher x-ray absorption characteristics than iodinated CT agents (8,9,14,15). Recently, Kopelman and co-workers have demonstrated the feasibility of using targeted AuNPs embedded in cancer cells for CT imaging under in vitro conditions (16).…”

mentioning

confidence: 70%

“…For example, 99m Tc (H 2 O)(CO) 3 -Dpr-(SSS)-BBN [7][8][9][10][11][12][13][14]NH 2 showed an uptake of 23.3% ID/g and 10.2% ID/g in pancreas and intestines, respectively, 1 h post injection (31), whereas 99m Tc(litorin) showed 23.56% ID/g in pancreas 30 min post injection (32). 177 Lu-DOTA-8-Aoc-BBN [7][8][9][10][11][12][13][14]NH 2 has shown 38.5% ID/g in pancreas and 5.60% ID/g in intestines (33). The slower uptake of 198 AuNP-BBN-3 nanoparticles in kidney (2.46% ID/g after 4 h and 1.58% ID/g after 24 h) suggests that smaller nanoconjugates ( 198 AuNP-BBN-3 <5 nm) are excreted through either the urinary or the hepatobiliary pathway.…”

Section: Resultsmentioning

confidence: 99%

“…To further probe the role of the AuNP-BBN conjugate as a GRP-receptorspecific candidate, a nonspecific agent such as gum Arabic protein functionalized AuNPs (GA-198 AuNP) (8), which have no affinity to GRP receptors, were injected in prostate-tumor-bearing mice, and the results of accumulation of gold in GRP receptor-avid pancreatic tissue were compared with those obtained from similar studies using the GRP-receptor-specific 198 AuNP-BBN-3 conjugate. It is important to recognize that the GA-198 AuNP conjugate is an excellent comparison standard as this nonspecific nanoparticulate agent possesses comparable size characteristics (core size: 13 nm; hydrodynamic size: 85 nm) to that of the target-specific 198 AuNP-BBN-3 conjugate.…”

Section: Resultsmentioning

confidence: 99%

“…In particular, nanoparticles of gold have already demonstrated "proof of concept" for diagnosis and therapy of various different types of cancers and thus present realistic potential for clinical translation (8)(9)(10)(11)(12). On the molecular imaging front, gold with a K-edge at 80.7 keV has higher absorption than iodine (K-edge at 33 keV), thus minimizing bone and tissue interference, which results in better contrast with a lower x-ray dose (13).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity

Chanda¹,

Kattumuri²,

Shukla³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

285

245

View full text Add to dashboard Cite

Development of cancer receptor-specific gold nanoparticles will allow efficient targeting/optimum retention of engineered gold nanoparticles within tumors and thus provide synergistic advantages in oncology as it relates to molecular imaging and therapy. Bombesin (BBN) peptides have demonstrated high affinity toward gastrin-releasing peptide (GRP) receptors in vivo that are overexpressed in prostate, breast, and small-cell lung carcinoma. We have synthesized a library of GRP receptor-avid nanoplatforms by conjugating gold nanoparticles (AuNPs) with BBN peptides. Cellular interactions and binding affinities (IC 50 ) of AuNP-BBN conjugates toward GRP receptors on human prostate cancer cells have been investigated in detail. In vivo studies using AuNP-BBN and its radiolabeled surrogate 198 AuNP-BBN, exhibiting high binding affinity (IC 50 in microgram ranges), provide unequivocal evidence that AuNP-BBN constructs are GRP-receptor-specific showing accumulation with high selectivity in GRP-receptor-rich pancreatic acne in normal mice and also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice. The i.p. mode of delivery has been found to be efficient as AuNP-BBN conjugates showed reduced RES organ uptake with concomitant increase in uptake at tumor targets. The selective uptake of this new generation of GRP-receptor-specific AuNP-BBN peptide analogs has demonstrated realistic clinical potential in molecular imaging via x-ray computed tomography techniques as the contrast numbers in prostate tumor sites are severalfold higher as compared to the pretreatment group (Hounsfield unit = 150).gold nanoparticles | bombesin | gastrin-releasing peptide receptor | prostate cancer | computed tomography imaging

show abstract

mentioning

confidence: 70%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity

Chanda¹,

Kattumuri²,

Shukla³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

285

245

View full text Add to dashboard Cite

show abstract

“…Application of nanoparticle treatment makes it possible to significantly reduce the size of the tumor before surgical resection and is an important milestone towards the ultimate ability of complete and irreversible tumor resolution without surgery. This ability has been demonstrated in animal trials and is presently at the stage of human clinical trials [35] [36].…”

Section: Interaction Of Nanoparticles With Cellsmentioning

confidence: 95%

Plasmas meet nanoparticles—where synergies can advance the frontier of medicine

Kong¹,

Keidar²,

Ostrikov³

2011

J. Phys. D: Appl. Phys.

107

View full text Add to dashboard Cite

To cite this version:M G Kong, M Keidar, K Ostrikov. Plasmas meet nanoparticleswhere synergies can advance the frontier of medicine. Journal of Physics D: Applied Physics, IOP Publishing, 2011, 44 (17) AbstractNanoparticles and low-temperature plasmas have been developed, independently and often along different routes, to tackle the same set of challenges in biomedicine. There are intriguing similarities and contrasts in their interactions with cells and living tissues, and these are reflected directly in the characteristics and scope of their intended therapeutic solutions, in particular their chemical reactivity, selectivity against pathogens and cancer cells, safety to healthy cells and tissues, and targeted delivery to diseased tissues. Time has come to ask the inevitable question of possible plasma-nanoparticle synergy and the related benefits to the development of effective, selective, and safe therapies for modern medicine. This perspective article offers a detailed review of the strengths and weakenesses of nanomedicine and plasma medicine as a stand-alone technology, and then provides a critical analysis of some of the major opportunities enabled by synergising the nanotechnology and the plasma technology. It is shown that the plasma-nanoparticle synergy is best captured through the plasma nanotechnology and its benefits for medicine are highly promising.

show abstract

Nano‐sized Carrier Systems as New Materials for Nuclear Medicine

Hrubý

2012

Intelligent Nanomaterials

View full text Add to dashboard Cite

Materials with nano-sized architecture currenly attract a lot of attention for various applications because they possess many unique properties. Several of the currently most studied applications of nanotechnology are in medicine, especially in the delivery of chemical drugs, and also in nuclear medicine, which is the focus of this review. The main areas of interest for nano-sized systems exploitable in nuclear medicine are imaging of reticuloendothelial system by single photon emission tomography, radiosynovectomy with beta-emitter-labeled particles, and diagnostic or therapeutic cancer applications exploiting passive targeting of radionuclides to solid tumors by enhanced permeation and retention (EPR) effect, or by active targeting approaches.

show abstract

Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing mice

Cited by 203 publications

References 38 publications

Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity

Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity

Plasmas meet nanoparticles—where synergies can advance the frontier of medicine

Nano‐sized Carrier Systems as New Materials for Nuclear Medicine

Contact Info

Product

Resources

About